亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

BCL-8 cloning, expression and its uses in Diffuse Large Cell Lymphoma

總結
Lead Inventors: Riccardo Dalla-Favera M.D.Problem or Unmet Need:Diffuse Large Cell Lymphoma (DLCL) is a fast-growing, aggressive form of non-Hodgkin lymphoma (NHL), a cancer of the body's lymphatic system. The standard treatment of DLCL is chemotherapy and radiation therapy, which have a lot of side effects. In addition, the treatment and prognosis depends on accurate diagnosis and staging information. Conventional diagnostic method is biopsy of patient tissues, which has its limitations in tissue sampling, patients' tolerability and diagnostic efficacy. Molecular diagnostic method and new therapeutic approach might shed light to DLCL patients. However, lack of new markers associated with this disease constitutes a barrier for further development. BCL-8 is a novel gene identified in pathogenesis of lymphoma. This invention provided an isolated nucleic acid encoding BCL-8 and its uses in DLCL. The genomic region of BCL-8 has been identified which is a recurrent site of rearrangement in a fraction of DLCL patients. This invention provides isolated nucleic acid encoding BCL-8 and oligonucleotides hybridizing with it. In addition, this invention provides an anti-body specific for BCL-8 and agents that block BCL-8 expression. This invention also provides methods for diagnosing DLCL. This invention further provides various methods of treating and preventing DLCL. The cloning and expression of this gene will provide new diagnostic and therapeutic approach for DLCL.
技術優勢
Molecular diagnostic method improves diagnostic efficacy and is not limited by resolution of microscope and sufficiency of sample compared with conventional biopsy method Antibody recognizing BCl-8 could be potentially developed into drug that has fewer side effects compared to chemotherapy/radiation approach Agent that inhibits the expression of BCL-8 can selectively target BCL-8 unlike many cancer drugs that affect cancer cells and normal cells The invention allows using the small molecule to inhibit the expression of BCL-8, which is easy to deliver in vivo
技術應用
Molecular diagnostic methods for detecting DLCL Therapeutic compound to treat patients with DLCL instead of traditional chemotherapy
詳細技術說明
The genomic region of BCL-8 has been identified which is a recurrent site of rearrangement in a fraction of DLCL patients. This invention provides isolated nucleic acid encoding BCL-8 and oligonucleotides hybridizing with it. In addition, this ...
*Abstract
None
*Inquiry
Peter Golikov Columbia Technology Ventures Tel: (212) 854-8444 Email: TechTransfer@columbia.edu
*IR
718 aka SK764
*Principal Investigation
*Publications
Dyomin VG, Rao PH, Dalla-Favera R, Chaganti RS. BCL8, a novel gene involved in translocations affecting band 15q11-13 in diffuse large-cell lymphoma. (1997) Proc Natl Acad Sci USA. 94(11): 5728-32
*Web Links
USPTO: US 6,309,860
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備